Dr. Jerome Sarris

Neurala Biosciences is an Australian clinical-stage biotechnology company developing second-generation psychedelic neuromedicines for mental health and addiction. Co-founded by Professor Jerome Sarris and Associate Professor Daniel Perkins, the company utilizes a proprietary DMT-harmala chemistry platform to create precision-engineered, botanically derived therapies. Its lead candidates include NBX-100, a medium-duration oral formulation for substance use disorders, and NBX-200, a short-acting intranasal formulation for chronic depressive illness. Neurala has successfully completed a Phase 1 clinical trial for its multi-harmala DMT formulation, demonstrating strong clinical signals and safety. The company is backed by seed funding from Tin Alley Ventures and the Genesis Pre-Seed Fund, and collaborates with partners such as CSIRO and IDT Australia.